Eli Lilly and Company (LLY)vsViemed Healthcare Inc (VMD)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
VMD
Viemed Healthcare Inc
$9.96
+0.71%
HEALTHCARE · Cap: $380.22M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 24015% more annual revenue ($65.18B vs $270.28M). LLY leads profitability with a 31.7% profit margin vs 5.5%. VMD trades at a lower P/E of 26.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
VMD
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+57.1%
Fair Value
$19.68
Current Price
$9.96
$9.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Revenue surging 25.5% year-over-year
Earnings expanding 29.8% YoY
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Moderate valuation
Smaller company, higher risk/reward
5.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : VMD
The strongest argument for VMD centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 25.5% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : VMD
The primary concerns for VMD are P/E Ratio, Market Cap, Profit Margin.
Key Dynamics to Monitor
VMD carries more volatility with a beta of 1.16 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 56/100), backed by strong 31.7% margins and 42.6% revenue growth. VMD offers better value entry with a 57.1% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?